Angiotensin II synergizes with BAFF to promote atheroprotective regulatory B cells
Abstract
Angiotensin II (AngII) promotes hypertension, atherogenesis, vascular aneurysm and impairs postischemic cardiac remodeling through concerted roles on vascular cells, monocytes and T lymphocytes. However, the role of AngII in B lymphocyte responses is largely unexplored. Here, we show that chronic B cell depletion (Baffr deficiency) significantly reduces atherosclerosis in Apoe −/− mice infused with AngII. While adoptive transfer of B cells in Apoe −/− /Baffr −/− mice reversed atheroprotection in the absence of AngII, infusion of AngII in B cell replenished Apoe −/− /Baffr −/− mice unexpectedly prevented the progression of atherosclerosis. Atheroprotection observed in these mice was associated with a significant increase in regulatory CD1d hi CD5 + B cells, which produced high levels of interleukin (IL)-10 (B10 cells). Replenishment of Apoe −/− /Baffr −/− mice with Il10 −/− B cells reversed AngII-induced B cell-dependent atheroprotection, thus highlighting a protective role of IL-10 + regulatory B cells in this setting. Transfer of AngII type 1A receptor deficient (Agtr1a −/−) B cells into Apoe −/− /Baffr −/− mice substantially reduced the production of IL-10 by B cells and prevented the AngII-dependent atheroprotective B cell phenotype. Consistent with the in vivo data, AngII synergized with BAFF to induce IL-10 production by B cells in vitro via AngII type 1A receptor. Our data demonstrate a previously unknown synergy between AngII and BAFF in inducing IL-10 production by B cells, resulting in atheroprotection.
Domains
Life Sciences [q-bio]Origin | Publisher files allowed on an open archive |
---|